Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
about
Preexposure prophylaxis for HIV prevention: where have we been and where are we going?Engaging HIV care providers in conversations with their reproductive-age patients about fertility desires and intentions: a historical review of the HIV epidemic in the United StatesElimination of perinatal HIV infection in the USA and other high-income countries: achievements and challengesOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesHIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Care of the HIV-infected pregnant woman in the developed worldAntiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxisPharmacokinetics of the Antiviral Lectin Griffithsin Administered by Different Routes Indicates Multiple Potential UsesThe cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studiesThe lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applicationsStrong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Knowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.Personalized Biobehavioral HIV Prevention for Women and Adolescent Girls.Attitude towards antiretroviral Pre-Exposure Prophylaxis (PrEP) prescription among HIV specialists.Sexual Behavior Patterns and PrEP Dosing Preferences in a Large Sample of North American Men Who Have Sex With Men.Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013-2014Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colorado.Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as preventionHIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative studyPreparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis.High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.Provider Attitudes toward Discussing Fertility Intentions with HIV-Infected Women and Serodiscordant Couples in the USASyphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.The need for multipurpose prevention technologies in sub-Saharan Africa.A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunityAccess to healthcare, HIV/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the US.Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention.Streamlining HIV testing for HIV preexposure prophylaxis.Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern ThailandChronic binge alcohol consumption does not diminish effectiveness of continuous antiretroviral suppression of viral load in simian immunodeficiency virus-infected macaques.Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxisInclusion of trans women in pre-exposure prophylaxis trials: a reviewClinician attitudes toward CDC interim pre-exposure prophylaxis (PrEP) guidance and operationalizing PrEP for adolescents.Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England.Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.
P2860
Q26825042-D703E107-221B-4D6D-9E0A-49490A725B84Q26829472-A88AD6DB-97ED-4B57-BC53-F556C1C21B13Q26998146-79FEEBCA-8784-49BE-A012-50F009ED0C9AQ27023352-DE3C5EB1-326E-4C9A-9E72-1F4E98E8A701Q27687375-9199E8F3-3A04-4AFA-8C17-478D07E2D354Q28082774-6BFB856A-3E87-4B35-A95F-0051954E8127Q28085433-30EF69C2-EF35-45B0-A35F-C0845CBD8E18Q28354743-7E520A7B-D7F4-491F-A3D0-67BE9FA9F214Q28487926-F7778315-9737-4710-A502-1D8C8BF726E9Q28533345-4A2AB613-7B98-4C3A-A6EF-83047C77E9DBQ28538457-041A31D8-9758-4D12-B8B9-0EB5B4CE34FAQ28547765-C4011016-4CFB-4E73-9427-2CF5D4163537Q30238750-F9354BBB-428E-476B-AC39-B20426417481Q30357818-1A7A10A6-7171-4F63-A98E-796FAF4754ACQ30539971-84B4532A-4259-4B5B-B85B-4A7EA3DA61CFQ30698590-1568C93C-E144-4028-AB45-479B0A00CB49Q33629173-020D1406-7EF9-45AD-B985-8FBC98916B38Q33696533-8F203AF3-3F63-417D-89B5-0F1CD71B5933Q33733039-BD5824E0-FD1D-4B21-BE2C-87AFAEBFC49AQ33765789-C0EDFE97-9F0B-4229-BE6E-B0DD01CB5990Q33792136-E9901592-D1AD-46DB-9D66-A45FF6306B81Q33854562-EB868730-0646-46D7-BC04-CECB620860F4Q34022199-97F432B9-2FDB-4260-8803-927445B8D914Q34061718-0EA40250-05B9-4F0C-AB84-AEFA45D87B9CQ34110847-C7F411CC-64C9-47DF-86A0-0404C582DEB2Q34163375-18EE98CF-6386-47CD-B74F-1294ABA4E2DAQ34202159-58F5B8EF-EBFB-4A0F-B9BD-E29839F95ECCQ34390282-B4B74413-C55E-4315-B93E-02CA4A5408F7Q34399535-3A0EB7AE-950E-433B-A0B2-3A11FBB35544Q34489373-002B7E8A-0667-4672-9992-6A0918352AB5Q34731242-FB75118D-D6A9-4F0B-B721-6398BF81CAFAQ34916430-F789305C-FFF2-4F06-8FCE-D3A601D9E3A0Q35014785-6018903C-3E31-4886-91CD-3A1B10185AB4Q35022815-10D60EB3-FBA1-4269-9C92-26038BD00D41Q35102317-21FE446C-37D7-47E3-90D1-12E869B497E6Q35108128-713F6762-2906-44F7-9867-4392558736FDQ35230239-279104CE-A420-4E7D-A976-8DACCD2F46D4Q35473669-0FDC45EE-777A-4350-B210-CC2C69449FD8Q35683071-A1BF880D-DD85-4959-82F4-3A3D1DE7BE08Q35798274-5BFAA8B2-8627-437B-997D-2F25C371BDD8
P2860
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Interim guidance for clinician ...... heterosexually active adults.
@en
Interim guidance for clinician ...... heterosexually active adults.
@nl
type
label
Interim guidance for clinician ...... heterosexually active adults.
@en
Interim guidance for clinician ...... heterosexually active adults.
@nl
prefLabel
Interim guidance for clinician ...... heterosexually active adults.
@en
Interim guidance for clinician ...... heterosexually active adults.
@nl
P1476
Interim guidance for clinician ...... heterosexually active adults.
@en
P304
P577
2012-08-01T00:00:00Z